Today, the CMO of Intercept Pharma (NASDAQ: ICPT), David Shapiro, sold shares of ICPT for $547.9K.
Following David Shapiro’s last ICPT Sell transaction on October 04, 2017, the stock climbed by 39.5%.
See today’s analyst top recommended stocks >>
Based on Intercept Pharma’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $43.58 million and GAAP net loss of $75.19 million. In comparison, last year the company earned revenue of $30.89 million and had a GAAP net loss of $86.56 million. The Company has a Price to Book ratio of 22.6572. Currently, Intercept Pharma has an average volume of 281.5K.
Based on 9 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $124.38, reflecting a 10.7% upside.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
